SS Innovations International Inc. (NASDAQ: SSII) has announced the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo, utilizing the company's SSi Mantra 3.0 surgical robotic system. The program's inaugural procedure was a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This milestone represents a significant step forward in the adoption of robotic-assisted cardiac surgery in South Asia and underscores the growing global reach of SS Innovations' technology.
The introduction of robotic cardiac surgery in Sri Lanka is important because it brings advanced, minimally invasive surgical options to a new region, potentially improving patient outcomes and expanding access to high-quality care. According to a recent company video describing the program's early activity, Kings Hospital has already completed more than 25 robotic procedures in just three weeks, demonstrating rapid adoption and proficiency with the SSi Mantra system. This swift uptake suggests strong local demand and confidence in the technology, which could pave the way for further expansion across Sri Lanka and neighboring countries.
SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter, reflecting the company's growing international footprint. The company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528, pointing to rising utilization of the company's installed base. These figures indicate that not only is the installed base expanding, but surgeons are increasingly using the systems for more procedures, which is a key driver of recurring revenue and long-term growth.
The next major corporate milestone is regulatory expansion, with SS Innovations pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. Achieving these certifications would open up the world's two largest markets for medical devices, potentially accelerating revenue growth and solidifying the company's position as a global player in surgical robotics. The successful launch in Sri Lanka serves as a proof point of the system's capabilities and could support regulatory submissions by demonstrating clinical utility and safety in a real-world setting.
For investors, this news matters because it highlights SS Innovations' ability to penetrate new markets and drive adoption of its robotic surgery platform. The company's focus on cardiac surgery, a complex and high-value specialty, differentiates it from competitors and positions it to capture a significant share of the growing robotic surgery market. As SS Innovations continues to expand its global presence and pursue regulatory approvals, it may become an increasingly attractive investment opportunity in the medtech sector.
The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. For more information about TechMediaWire, please visit https://www.TechMediaWire.com.
